Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of March 2021, specifically reporting a transaction notification dated March 23, 2021. The filing serves as a disclosure of a transaction involving a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to a specific insider transaction notification and does not contain consolidated financial statements.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely details an acquisition of American Depositary Shares (ADSs) by Dr. H Barron, Chief Scientific Officer and President, R&D, within his Executive Supplemental Savings Plan account.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a regulatory disclosure of a single transaction executed on March 22, 2021, on the New York Stock Exchange (XNYS).
Important Facts for Investors
- Transaction Type: Acquisition of notional ADSs by a senior executive.
- Executive Involved: Dr. H Barron (Chief Scientific Officer and President, R&D).
- Transaction Volume: 1,221.311 ADSs.
- Transaction Price: $36.6700 per ADS.
- Transaction Date: March 22, 2021.
- Market: New York Stock Exchange (XNYS).